New Drugs for the Treatment of Advanced-Stage Diffuse Large Cell Lymphomas

Seminars in Hematology

Volumn 43, Issue 4, 2006, Pages 251-261

  O'Connor, Owen A ^a   Hamlin, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 PHENYLBUTYRIC ACID; AMG 623; ANTINEOPLASTIC AGENT; APRIL PROTEIN; BELIMUMAB; BORTEZOMIB; DEPSIPEPTIDE; ENZASTAURIN; EPOTHILONE B; FR 901228; GX 15 070; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IPSI 001; ISOSORBIDE; IXABEPILONE; KINESIN SPINDLE PROTEIN INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PEPTIDE DERIVATIVE; PR 171; PRALATREXATE; PREMETREXED; PROTEIN BCL 2; PROTEIN BCL 6; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ADVANCED CANCER; ANOREXIA; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL SURVIVAL; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FATIGUE; GENETIC TRANSCRIPTION; HUMAN; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; DRUG DESIGN; FOLIC ACID ANTAGONISTS; HISTONE DEACETYLASES; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCL-6; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749244668     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.07.002     Document Type: Article

References (68)

1. Ye B.H., Lista F., Lo Coco F., et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262 (1993) 747-750
2. Ye B.H., Rao P.H., Chaganti R.S., et al. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma. Cancer Res 53 (1993) 2732-2735
3. Ye B.H., Chaganti S., Chang C.C., et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J 14 (1995) 6209-62017
4. Dent A.L., Shaffer A.L., Yu X., et al. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 276 (1997) 589-592
5. Shaffer A.L., Yu X., He Y., et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13 (2000) 199-212
6. Pasqualucci L., Bereschenko O., Niu H., et al. Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6. Leuk Lymphoma 44 suppl 3 (2003) S5-S12
7. Capello D., Vitolo U., Pasqualucci L., et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 95 (2000) 651-659
8. Bereshchenko O.R., Gu W., and Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 32 (2002) 606-613
9. Luo J., Nikolaev A.Y., Imai S., et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107 (2001) 137-148
10. Vaziri H., Dessain S.K., Ng Eaton E., et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107 (2001) 149-159
11. Imai S., Armstrong C.M., Kaeberlein M., et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403 (2000) 795-800
12. Kelly W.K., O'Connor O.A., and Marks P.A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 11 (2002) 1695-1713
13. Kelly W.K., Richon V.M., O'Connor O., et al. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9 (2003) 3578-3588
14. O'Connor O.A., Heaney M.L., Schwartz L., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24 (2006) 166-173
15. Kelly W.K., O'Connor O.A., Krug L.M., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23 (2005) 3923-3931
16. Piekarz R.L., Robey R.W., Zhan Z., et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103 (2004) 4636-4643
17. Piekarz R.L., Robey R., Sandor V., et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood 98 (2001) 2865-2868
18. Duvic M.T.R., Zhang C., Goy A., Richon V., and Frankel S. Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy. J Clin Oncol 23 (2005) 16S (abstr 6571)
19. Ryan Q.C., Headlee D., Acharya M., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23 (2005) 3912-3922
20. Prive G.G., Melnick A., Ahmad K.F., and Licht J.D. The BTB domain zinc finger proteins. In: Iuchi S., and Kuldell N. (Eds). Zinc Finger Proteins: From Atomic Contact to Cellular Function (2005), Landes Bioscience, Austin, TX
21. Polo J.M., Dell'Oso T., Ranuncolo S.M., et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 10 (2004) 1329-1335
22. Reed J.C. Dysregulation of apoptosis in cancer. J Clin Oncol 17 (1999) 2941-2953
23. Reed J.C. Bcl-2 and the regulation of programmed cell death. J Cell Biol 124 (1994) 1-6
24. Cleary M.L., Smith S.D., and Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47 (1986) 19-28
25. Tsujimoto Y., Gorham J., Cossman J., et al. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229 (1985) 1390-1393
26. Tsujimoto Y., and Croce C.M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A 83 (1986) 5214-5218
27. Yang J., Liu X., Bhalla K., et al. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked. Science 275 (1997) 1129-1132
28. Kluck R.M., Bossy-Wetzel E., Green D.R., et al. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275 (1997) 1132-1136
29. Rai K., Wallace P., Soho C., Landrigan B., Meyn P., Wei T., et al. Efficacy and safety of the combination of genasense fludarabine and rituximab in previously treated and untreated subjects with chronic lymphocytic leukemia. Blood 106 (2005) (abstr 2129)
30. O'Brien S.M., Cunningham C.C., Golenkov A.K., et al. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 7697-7702
31. O'Connor O.A., Smith E.A., Toner L.E., et al. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 12 (2006) 2902-2911
32. Wu D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs 38 (1989) 333-341
33. Tuszynski G.P., and Cossu G. Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res 44 (1984) 768-771
34. Coyle T., Levante S., Shetler M., et al. In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neurooncol 19 (1994) 25-35
35. Gilbert N.E., O'Reilly J.E., Chang C.J., et al. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci 57 (1995) 61-67
36. Wang X., Wang J., Wong S.C., et al. Cytotoxic effect of gossypol on colon carcinoma cells. Life Sci 67 (2000) 2663-2671
37. Flack M.R., Pyle R.G., Mullen N.M., et al. Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76 (1993) 1019-1024
38. Van Poznak C., Seidman A.D., Reidenberg M.M., et al. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial. Breast Cancer Res Treat 66 (2001) 239-248
39. Bushunow P., Reidenberg M.M., Wasenko J., et al. Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 43 (1999) 79-86
40. Liu S., Kulp S.K., Sugimoto Y., et al. The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anticancer Res 22 (2002) 33-38
41. Oliver C.L., Bauer J.A., Wolter K.G., et al. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res 10 (2004) 7757-7763
42. Paoluzzi L., Gonen M., Toner L., Smith E., Yang D., Holmund J., et al. Targeting antiapoptotic BcL-2 family members with AT-101 in pre-clinical models of aggressive lymphoma in combination with cyclophosphamide (C) and rituximab (R) produces a marked improvement in therapeutic efficacy. Blood 106 (2005) (abstr 926)
43. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435 (2005) 677-681
44. Petros A.M., Dinges J., Augeri D.J., et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem 49 (2006) 656-663
45. Sirotnak F.M., DeGraw J.I., Moccio D.M., et al. New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12 (1984) 18-25
46. Wang E.S., O'Connor O., She Y., et al. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 44 (2003) 1027-1035
47. Sirotnak F.M., DeGraw J.I., Chello P.L., et al. Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice. Cancer Treat Rep 66 (1982) 351-358
48. Sirotnak F.M. Obligate genetic expression in tumor cells of a fetal membrane property mediating "folate" transport: Biological significance and implications for improved therapy of human cancer. Cancer Res 45 (1985) 3992-4000
49. Chiao J.H., Roy K., Tolner B., et al. RFC-1 gene expression regulates folate absorption in mouse small intestine. J Biol Chem 272 (1997) 11165-11170
50. DeGraw J.I., Colwell W.T., Piper J.R., et al. Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 36 (1993) 2228-2231
51. O'Connor O.A., Hamlin P., Neylon E., Moskowitz C., Portlock C., Straus D., et al. Pralatrexate (10-Propargyl-10-Deazaaminopterin(PRX)), a novel antifolate, effects durable complete remissions (CR) in patients with a diversity of drug resistant T-cell lymphomas with minimal toxicity. Blood 106 (2005) (abstr 2678)
52. Mackay F., Woodcock S.A., Lawton P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 190 (1999) 1697-1710
53. Do R.K., Hatada E., Lee H., et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192 (2000) 953-964
54. Khare S.D., Sarosi I., Xia X.Z., et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 97 (2000) 3370-3375
55. Novak A.J., Grote D.M., Ziesmer S.C., et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 24 (2006) 983-987
56. Elsawa S.F., Novak A.J., Grote D.M., et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Blood 107 (2006) 2882-2888
57. Dillon S.R., Gross J.A., Ansell S.M., et al. An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5 (2006) 235-246
58. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
59. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23 (2005) 4117-4126
60. Habermann T.W.E., Morrison V.A., Cassileth P.A., Cohn J., Dakhil S., Gascoyne R.D., et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL). Blood 104 (2004) 40a (abstr)
61. Pfreundschuh M., Trumper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7 (2006) 379-391
62. Skvortsova I., Popper B.A., Skvortsov S., et al. Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. J Radiat Res (Tokyo) 46 (2005) 241-248
63. Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 3793-3803
64. Zelenetz A., Salen M., Vose J., Younes A., and Kaminski M. Patients with transformed low grade lymphoma attain durable responses following out-patient radioimmunotherapy with tositumomab and iodine I 131 tositumomab. Blood 100 (2002) 357 (abstr 1384)
65. Morschhauser F., Huglo D., and Martinelli G. Yttrium-90 ibrituomomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large b-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open-label phase II trial. Blood 104 (2004) 41a (abstr)
66. Hamlin P., Moskowitz C.H., and Wegner B. Early safety and efficacy analysis of a phase II study of sequential R-CHOP and yttrium-90 ibritumomab tiuxetan (Zevalin) for elderly high risk patients with untreated DLBCL. Blood 106 (2005) (abstr 926)
67. Gopal A., Rajendran J., Gooley T.A., Pagel J., Fisher D., Petersdorf S., et al. A phase II study of myeloablative I-131-anti-CD20 (tositumomab) radioimmunotherapy (RIT) and autologous hematopoietic stem cell transplantation (ASCT) for adults ≥ 60 years of age with high-risk, relapsed, or refractory B-cell lymphoma. Blood 106 (2005) (abstr 487)
68. Pervan Milena J.C., Matso D., et al. Active combination therapy of bortezomib (Velcade) and ibritumomab tiuxetan (Zevalin) in an in vivo diffuse large B-cell lymphoma model. Blood (2005)